Intelligence · Clinical Pipeline
Dyne Therapeutics Pipeline
All ClinicalTrials.gov programs at Dyne Therapeutics — phase, modality, and trial IDs.
- Programs
- 6
Quick answer
Dyne Therapeutics has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
SODIUM CHLORIDE , DYNE-101
Dyne Therapeutics
Myotonic Dystrophy Type 1
1 trial -
zeleciment basivarsen (DYNE-101)
Dyne Therapeutics
Myotonic Dystrophy Type 1 (DM1)
1 trial -
DYNE-101
Dyne Therapeutics
Myotonic Dystrophy Type 1 (DM1)
1 trial -
DYNE-101, The placebo is commercially available 0.9% (w/v) saline solution intended for IV
Dyne Therapeutics
Myotonic Dystrophy Type 1
1 trial -
DYNE-251
Dyne Therapeutics
Duchenne Muscular Dystrophy (DMD)
1 trial -
The placebo is commercially available 5% dextrose solution intended for IV, DYNE-251, DYNE-251
Dyne Therapeutics
Duchenne muscular dystrophy
1 trial
Frequently asked questions
How many pipeline programs does Dyne Therapeutics have?
6 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs